Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 02 - 25 tags : Phase 3 save search
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Published: 2021-02-25 (Crawled : 19:00) - biospace.com/
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.37%
H: 1.02%
C: -1.55%
covid phase 3 trial casirivimab
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
Published: 2021-02-25 (Crawled : 15:00) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: -1.6%
H: 6.82%
C: -10.71%
phase 3 trial enroll
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
Published: 2021-02-25 (Crawled : 15:00) - biospace.com/
KRON | $0.99 -3.88% -4.04% 120K
|
Health Technology
|
| O: -0.79%
H: 1.86%
C: 0.52%
phase 1 cancer trial phase 3 phase 2
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
Published: 2021-02-25 (Crawled : 15:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 2.76%
H: 6.91%
C: -1.86%
growth hormone china growth phase 3 hormone
Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
Published: 2021-02-25 (Crawled : 14:05) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 19.78%
H: 0.9%
C: -12.61%
covid phase 1 results phase 3 phase 2
Galiano Gold Provides Miradani North Phase 3 Drilling Update
Published: 2021-02-25 (Crawled : 12:10) - prnewswire.com
GAU | $1.48 -1.33% 0.0% 960K
|
Non-Energy Minerals
|
| O: -1.54%
H: 1.56%
C: -5.47%
phase 3
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
Published: 2021-02-25 (Crawled : 12:05) - globenewswire.com
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: -3.93%
H: 4.68%
C: -8.56%
covid adcovid phase 1 vaccine trial phase 3 phase 2 enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.